Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOUR006 dose-ranging study in active moderate-to-severe thyroid eye disease
2024-514801-69-00Phase 2Authorised
- Sponsor
- Tourmaline Bio, Inc.
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial in Graves Orbitopathy (GO) comparing TOUR006 treatment arm(s) with Placebo (2 arms). Primary endpoint: Proptosis response at Week 20. Planned start Apr 2025; status: authorised.
02
Drugs
pacibekitug
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on 2024-514801-69-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514801-69-00.